Sensorineural Hearing Loss (disorder)
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hyperparathyroidism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hypothyroidism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Respiratory Insufficiency
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Speech Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Tracheal Stenosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Vertigo
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Compensated hypothyroidism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Vestibular dysfunction
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cochlear malformation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Congenital sensorineural hearing loss
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hypoplasia of the cochlea
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Intellectual Disability
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cystic Fibrosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Finally, we identified a novel, rare cell type that we call the 'pulmonary ionocyte', which co-expresses FOXI1, multiple subunits of the vacuolar-type H<sup>+</sup>-ATPase (V-ATPase) and CFTR, the gene that is mutated in cystic fibrosis.
|
30069046 |
2018 |
Cystic Fibrosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Knockout of Foxi1 in mouse ionocytes causes loss of Cftr expression and disrupts airway fluid and mucus physiology, phenotypes that are characteristic of cystic fibrosis.
|
30069044 |
2018 |
Anemia, Hemolytic, Congenital
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additional manifestations include bone demineralization (rickets, osteomalacia), growth deficiency, sensorineural hearing loss (in <i>ATP6V0A4-</i>, <i>ATP6V1B1-</i>, and <i>FOXI1-</i>dRTA), and hereditary hemolytic anemia (in some individuals with <i>SLC4A1-</i>dRTA).
|
31600869 |
2019 |
Oncocytoma, renal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although the origin of RO remains unclear, our findings suggest that FOXI1 immunohistochemistry is useful in differential diagnosis of RO from chRCC with overlapping histology.
|
31177114 |
2019 |
Chromophobe Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although the origin of RO remains unclear, our findings suggest that FOXI1 immunohistochemistry is useful in differential diagnosis of RO from chRCC with overlapping histology.
|
31177114 |
2019 |
Distal Renal Tubular Acidosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutations in adenosine triphosphate ATP6V1 (B1 H<sup>+</sup>-ATPase subunit), ATPV0A4 (a4 H<sup>+</sup>-ATPase subunit), SLC4A1 (anion exchanger 1), and FOXI1 (forkhead transcription factor) cause distal renal tubular acidosis type I. Carbonic anhydrase II mutations affect several nephron segments and give rise to a mixed proximal and distal phenotype.
|
31300090 |
2019 |
Congenital diverticulum of pharynx
|
0.010 |
Biomarker
|
disease |
BEFREE |
Foxi1 promotes late-stage pharyngeal pouch morphogenesis through ectodermal Wnt4a activation.
|
29932895 |
2018 |
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Chromophobe RCCs express FOXI1-driven genes that define collecting duct intercalated cells, whereas HNF-regulated genes, specific for proximal tubule cells, are an integral part of clear cell and papillary RCC transcriptomes.
|
28793269 |
2017 |
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, to the best of our knowledge, our findings are the first to demonstrate that Foxi1 is a key player in the transcriptional control of miR-491-5p and that miR-491-5p acts as an anti-oncogene by targeting Wnt3a/β-catenin signaling in GC.
|
28358374 |
2017 |